SNHG16 accelerates the proliferation of primary cardiomyocytes by targeting miRNA7705p
The present study aimed to clarify the influence of long noncoding RNA small nuclear host gene 16 (lncRNA SNHG16) on cardiomyocyte proliferation following ischemia/reperfusion injury (IRI) and the potential mechanism. An IRI model in mice was established by performing ligation of the
anterior descending coronary artery (LAD). Primary cardiomyocytes were isolated from newborn mice and subjected to H2O2 treatment to mimic in vitro IRI. Relative levels of SNHG16 and miRNA7705p in both in vivo and in vitro IRI models were examined. The regulatory effects of
SNHG16 and miRNA7705p on the proliferative ability of H2O2treated cardiomyocytes were assessed by Cell Counting Kit8 (CCK8) and 5ethynyl2'deoxyuridine (EdU) assay. The binding relationship between SNHG16 and miRNA7705p was verified through dualluciferase reporter gene assay. It is found that
SNHG16 was timedependently downregulated in the IRI models. Overexpression of SNHG16 enhanced the proliferative ability of the cardiomyocytes. miRNA7705p was found to be a direct target of SNHG16. Moreover, SNHG16 was able to negatively regulate the miRNA7705p level. Overexpression of miRNA7705p
partially reversed the role of SNHG16 on accelerating cardiomyocyte proliferation. Collectively, SNHG16 accelerates the proliferative ability of cardiomyocytes following IRI by negatively regulating miRNA7705p.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
Document Type: Research Article
Department of Cardiac Surgery, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266003, P.R. China
Department of Otorhinolaryngology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266003, P.R. China
Department of Oncology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266003, P.R. China
October 1, 2020
More about this publication?
Experimental and Therapeutic Medicine aims to ensure the expedient publication, in both print and electronic format, of studies relating to biology, gene therapy, infectious disease, microbiology, molecular cardiology and molecular surgery. The journal welcomes studies pertaining to all aspects of molecular medicine, and studies relating to in vitro or in vivo experimental model systems relevant to the mechanisms of disease are also included.
All materials submitted to this journal undergo the appropriate review via referees who are experts in this field. All materials submitted follow international guidelines with regard to approval of experiments on humans and animals.
- Editorial Board
- Information for Authors
- Submit a Paper
- Subscribe to this Title
- Information for Advertisers
- Terms & Conditions
- Ingenta Connect is not responsible for the content or availability of external websites